ECM
ROIV icon

ExodusPoint Capital Management’s Roivant Sciences ROIV Stock Holding History

ExodusPoint Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-632,908
Closed -$9.58M – 1987
2025
Q3 		$9.58M Buy
632,908
+228,164
+56% +$2.82M 0.1% 211
2025
Q2 		$4.56M Buy
404,744
+296,378
+273% +$3.21M 0.04% 454
2025
Q1 		$1.09M Buy
+108,366
New +$1.17M 0.01% 896
2024
Q3 		– Sell
-304,207
Closed -$3.21M – 2025
2024
Q2 		$3.21M Buy
+304,207
New +$3.33M 0.02% 597
2024
Q1 		– Sell
-36,262
Closed -$407K – 1899
2023
Q4 		$407K Buy
36,262
+947
+3% +$9.23K ﹤0.01% 1093
2023
Q3 		$412K Buy
35,315
+1,935
+6% +$21.9K ﹤0.01% 1303
2023
Q2 		$336K Sell
33,380
-454,708
-93% -$4.07M ﹤0.01% 1494
2023
Q1 		$3.6M Buy
488,088
+439,783
+910% +$3.62M 0.03% 635
2022
Q4 		$386K Buy
+48,305
New +$269K 0.01% 1271

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ExodusPoint Capital Management's ROIV Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 632,908 shares — an estimated $9.58M sold.

ExodusPoint Capital Management first reported a position in ROIV in Q4 2022 and held it in 9 quarters. The position peaked at $9.58M in Q3 2025. 396 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

  • ExodusPoint Capital Management reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 632,908 Roivant Sciences shares in Q4 2025, an estimated $9.58M.
  • ExodusPoint Capital Management first reported a position in Roivant Sciences in Q4 2022 and held it in 9 quarters.
  • ExodusPoint Capital Management's Roivant Sciences position peaked at $9.58M in Q3 2025.
  • 396 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.